Apakah dividen Siegfried Holding aman?
Siegfried Holding meningkatkan dividen sejak 8 tahun.
Dalam kurun waktu 10 tahun terakhir, Siegfried Holding telah meningkatkan sebesar 10,976 % setiap tahunnya.
Dalam kurun waktu 5 tahun, naik pembagian dividen meningkat sebesar 7,215 %.
Analis memperkirakan untuk tahun fiskal yang sedang berjalan akan terjadi pertumbuhan sebesar Kenaikan Dividen%.
Siegfried Holding Aktienanalyse
Apa yang dilakukan Siegfried Holding?
The Siegfried Holding AG is a Swiss pharmaceutical company based in Zofingen, which operates worldwide. The company's history dates back to 1873, when the pharmacist and chemist Franz von Siegfried founded the "First Aid Pharmacy". Over the years, the company has developed into an important producer of pharmaceutical ingredients.
The business model of Siegfried Holding AG is based on the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. The products are used in various areas, such as veterinary medicine, human medicine, or the chemical industry.
Siegfried operates various divisions that focus on different segments of the value chain. These divisions include production, contract development and manufacturing (CDMO), and commercial products. In the production division, the company produces pharmaceutical ingredients and intermediate products. The CDMO business offers custom development and manufacturing services for the pharmaceutical and biotech industry. In the commercial products division, finished products such as cough medicine, antidepressants, or blood pressure reducers are distributed.
Among the products offered by Siegfried are the active ingredient carbamazepine, which is used as an anticonvulsant and for the treatment of bipolar disorder. Another active ingredient is acetaminophen, which is used as a painkiller and fever reducer. Siegfried also produces the active ingredient sotalol, which is used to treat heart rhythm disorders.
In the context of the CDMO business, Siegfried also develops and produces custom products for the pharmaceutical and biotech industry. This includes the manufacturing of clinical trial preparations, the implementation of process developments, and scale-up productions of active ingredients and finished products.
In recent years, Siegfried Holding AG has made several acquisitions to expand its business and strengthen its market presence. In 2016, the company acquired Bexbach-based Saltigo GmbH, a specialist in the production of customer-specific fine chemicals. Two years later, Siegfried acquired the active ingredient production business of Alcami, a US pharmaceutical company.
In summary, it can be said that Siegfried Holding AG is an established Swiss pharmaceutical company specializing in the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. In recent years, the company has made several acquisitions to expand its market presence and diversify its business. Siegfried Holding adalah salah satu perusahaan paling populer di Eulerpool.com.Rencana tabungan saham menawarkan kesempatan menarik bagi investor untuk membangun kekayaan jangka panjang. Salah satu keuntungan utamanya adalah efek rata-rata biaya: Dengan berinvestasi dalam jumlah tetap secara reguler ke dalam saham atau dana saham, otomatis anda akan membeli lebih banyak saham ketika harga rendah, dan lebih sedikit ketika harga tinggi. Hal ini dapat menghasilkan harga rata-rata per saham yang lebih menguntungkan seiring waktu. Selain itu, rencana tabungan saham juga memungkinkan investor kecil untuk mengakses saham-saham mahal, karena mereka dapat berpartisipasi dengan jumlah yang kecil. Investasi rutin juga mendukung strategi investasi yang disiplin dan membantu menghindari keputusan emosional, seperti membeli atau menjual secara impulsif. Di samping itu, investor juga mendapat manfaat dari potensi peningkatan nilai saham serta dari pembagian dividen, yang bisa direinvestasikan, meningkatkan efek bunga majemuk dan dengan demikian pertumbuhan dari modal yang diinvestasikan.